Melinda Lackey Joins Valion Bio as General Counsel to Leverage Legal Expertise

Valion Bio's Exciting New Chapter with Melinda Lackey's Leadership

Valion Bio, Inc., previously known as Tivic Health Systems, Inc. (Nasdaq: VBIO), has made a significant appointment in its leadership team by welcoming Melinda Lackey as General Counsel and Senior Vice President of Legal Affairs. This strategic move comes at a crucial time as the company advances its clinical-stage immunotherapeutics, especially focusing on its innovative drug, Entolimod™, designed for the treatment of Acute Radiation Syndrome (ARS) and supportive care in oncology.

Expertise to Fuel Growth

Melinda Lackey is not new to the intricacies of biopharmaceutical law. With nearly 20 years of overlapping experience in scientific research and legal practice, her background is particularly tailored to support Valion Bio’s ambitions in expanding their product pipeline. Before joining Valion, Ms. Lackey was the Senior Vice President of Legal Administration at Alaunos Therapeutics, where she was instrumental in managing compliance and navigating the legal landscapes of clinical trials and regulatory frameworks. This experience is essential for Valion Bio as they target an FDA Animal Rule approval for Entolimod™.

In her previous roles, Lackey honed her skills at Kuur Therapeutics and gained invaluable insights into the structural aspects of immunological drug development, consolidating her expertise in regulatory strategy and capital market obligations, notoriously critical for public companies. Her earlier legal career included impressive posts at prestigious law firms such as Winston Strawn LLP and Howrey LLP, where she specialized in patent litigation and biopharmaceutical transactions.

Melinda’s educational background further distinguishes her within the field. She holds a Juris Doctor from the University of Houston Law Center and started her career in science as a Research Associate at the University of Texas Health Science Center, later working at the renowned UT MD Anderson Cancer Center. This fusion of legal prowess and scientific understanding positions her uniquely to propel Valion Bio’s objectives.

Valion Bio's Strategic Aspirations

So, why is this appointment particularly noteworthy? Valion Bio is on a commendable journey to navigate the complexities associated with advancing Entolimod™ through the Animal Rule path in the FDA. This path could be pivotal for securing approvals for their groundbreaking therapy aiming to mitigate the effects of ARS, a significant concern for the government and military agencies. Moreover, with the establishment of their subsidiary Velocity Bioworks in San Antonio, Ms. Lackey's legal expertise will prove critical in supporting their operational needs as they scale forth.

Michael K. Handley, the Chief Executive Officer of Valion Bio, remarked on the significance of this new role. He emphasized that Melinda's dual experience in immunotherapy and legal strategy will be vital in supporting the company as they execute capital-raising efforts and continue to evolve operationally.

Ms. Lackey herself expressed her enthusiasm for joining Valion Bio at such a pivotal moment. With a promising pipeline that includes both Entolimod™ and the next-generation TLR5 agonist, Entolasta™, she sees the potential to protect and extend lives through innovative therapies. The combination of a clinical-stage pipeline with a robust governmental countermeasures initiative and operational manufacturing capabilities presents a unique legal framework that calls for creativity and precision — exactly what she aims to contribute.

Looking Forward

As Valion Bio gears up for the future, the presence of seasoned leaders like Melinda Lackey will undoubtedly shape its trajectory. With her extensive legal background and commitment to harnessing the potential of immunological therapies, the company is poised to make significant strides in biopharmaceutical development. The healthcare industry should keep a keen eye on Valion as it furthers its mission.

In summary, Melinda Lackey's entry into Valion Bio represents a strategic enhancement not just for the legal team but for the entire organization. Her expertise reflects Valion's commitment to advancing innovative solutions in the biopharma sector, ultimately benefiting countless patients seeking hope in the realm of untreatable conditions.